Philadelphia+ Chronic Myeloid Leukemia with CALR Mutation: A Case Report and Literature Review
- Author:
Seug Yun YOON
1
;
Sun Young JEONG
;
Changgon KIM
;
Min-Young LEE
;
Jieun KIM
;
Kyoung-Ha KIM
;
Namsu LEE
;
Jong-Ho WON
Author Information
- Publication Type:Case Report
- From:Cancer Research and Treatment 2020;52(3):987-991
- CountryRepublic of Korea
- Language:English
- Abstract: Myeloproliferative neoplasms (MPNs) are classified as chronic myeloid leukemia (CML) and Philadelphia chromosome-negative MPN. In MPN cases, the presence of a BCR-ABL1 translocation with a coexisting mutation is exceptionally rare. Herein, we report the first documented patient with CML harboring CALR mutation in Korea. A 33-year-old woman was referred to our hospital in February 2015 with splenomegaly, leukocytosis, and thrombocytosis. She was diagnosed with CML and started receiving nilotinib. In October 2015, a major molecular response was observed, but thrombocytosis persisted. A repeat bone marrow (BM) examination revealed no specific findings. However, as thrombocytosis worsened, we changed nilotinib to dasatinib. In May 2019, owing to persistent thrombocytosis, we repeated the BM examination and found CALR mutation (15.97%) on the MPN–next generation sequencing (NGS) test. We then retrospectively performed repeat MPN-NGS testing using the BM aspirate sample obtained in 2015 and found CALR mutation (10.64%).
